TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06039176

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
Study: NCT04886219

Intervention type: OTHER
Intervention: Eye examination
Description: * Multimodal fundus imaging (color fundus photography, optical coherence tomography (OCT))~* orthoptic assessment (Visual acuity, Refraction, Cover test, Stereopsis evaluation~* ocular biometry~* corneal topography~* monocular photographs in photopic and scotopic condition
Study: NCT05196867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Participants in the intervention group will receive (1) weekly telephone or videoconference coaching; (2) health education print materials and tip sheets;(3) navigation to programs and resources to help participants meet behavioral goals (e.g., fitness events, classes and webinars, etc); (4) text messages related to behavioral skills; (5) a Fitbit activity tracker and Aria scale; (6) resistance tubes and instructional video for strengthening exercise (if resistance exercise module is chosen); and (7) tools to manage portion sizes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Patients in the control arm will initially receive written education material about the risk factors for liver cancer and management options. They will be offered the intervention after they complete the 6-month assessment.
Study: NCT06039176

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically

Intervention type: DEVICE
Intervention: HeartMate 3 (R) left ventricular assist device
Description: No direct intervention; this is prospective study analysis of pump data from the HeartMate 3 (R) left ventricular assist device with clinical correlation to a multitude of variables and conditions we see clinically
Study: NCT06397456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Patient Education
Description: In-person patient education about CKD, CKD risk factor management and renal replacement therapy options.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment to Change
Description: Motivational interviewing to assist participants in committing to change in CKD management or RRT selection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood pressure monitoring
Description: Participants will learn how to check their blood pressure and will receive a blood pressure cuff for home.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Written Patient Education
Description: Written patient education booklet about general health care management including taking medications, having a primary care doctor, weight management and exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-based reinforcement for CKD self-management
Description: Patient educator will use text messages based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based education session, reinforcement for self-management
Description: Patient educator will use provide a booster session based on social cognitive theory to remind participants about and reinforce goals set around CKD self-management, blood pressure control and RRT selection

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Text-based reinforcement for general health self-management
Description: Patient educator will use text messages to send general health management messages
Study: NCT05156710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV020 (SAR445088)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV020 (SAR445088)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous immunoglobulin (IVIg)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab or biosimilar
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab or biosimilar
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG)
Description: Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Pharmaceutical Form: Tablet Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate
Description: Pharmaceutical Form: Tablet Route of Administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Pharmaceutical Form: Vary Route of Administration: Vary

Intervention type: DRUG
Group type: OTHER
Intervention: Corticosteroids
Description: Pharmaceutical Form: Vary Route of Administration: Vary
Study: NCT06475521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Test group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Formula
Description: Test group
Study: NCT04434664

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate
Description: The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol Succinate
Description: The interventions will be implemented in random order in a crossover (AB-BA) design, separated by an approximately one-week washout period
Study: NCT05472909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Relaxation Music
Description: Participants listen to standardized relaxation music during surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personal Choice of Music
Description: Participants listen to their preferred music during surgery.
Study: NCT06520345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-TLX591
Description: Participants randomized to Group A will receive two 76 mCi (±10%) doses of 177Lu-TLX591 14 days apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)
Study: NCT06500065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo dPET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-HA-DOTA-TATE
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo dPET/CT
Study: NCT06045299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+Brimonidine combination ophthalmic solution
Description: Aceclidine+Brimonidine combination ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine ophthalmic solution
Description: Aceclidine ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) ophthalmic solution
Description: Placebo (Vehicle) ophthalmic solution
Study: NCT06520345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles
Study: NCT06410950

Intervention type: DIAGNOSTIC_TEST
Intervention: MyotonPRO Assessment of Muscle Biomechanical Properties
Description: Muscle assessments will be conducted using the MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. Measurement patterns and subject data will be uploaded to the device via computer. Each evaluation will be performed bilaterally.~Subjects' muscle measurement points will be marked prior to assessment. The physiotherapist will position the device perpendicular to the muscle body and apply downward pressure (18N). Pressure should be maintained until the device's probe light changes from red to green. Five measurement pulses will then be applied. Each pulse lasts 15 ms with an 8 ms interval between pulses.~The SENIAM sensor location guide will be used to determine the approximate motor point for MyotonPRO measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: MyotonPRO Assessment of Muscle Biomechanical Properties
Description: Muscle assessments will be conducted using the MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. Measurement patterns and subject data will be uploaded to the device via computer. Each evaluation will be performed bilaterally.~Subjects' muscle measurement points will be marked prior to assessment. The physiotherapist will position the device perpendicular to the muscle body and apply downward pressure (18N). Pressure should be maintained until the device's probe light changes from red to green. Five measurement pulses will then be applied. Each pulse lasts 15 ms with an 8 ms interval between pulses.~The SENIAM sensor location guide will be used to determine the approximate motor point for MyotonPRO measurements.
Study: NCT04564547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: ISL capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: ISL capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: ISL capsule taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: Ulonivirine tablet taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: Ulonivirine tablet taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: Ulonivirine tablet taken by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF
Description: BIC/FTC/TAF tablet taken by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ISL
Description: Placebo capsule matched to ISL taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ulonivirine
Description: Placebo tablet matched to ulonivirine taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ulonivirine
Description: Placebo tablet matched to ulonivirine taken by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ulonivirine
Description: Placebo tablet matched to ulonivirine taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: Placebo tablet matched to BIC/FTC/TAF taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: Placebo tablet matched to BIC/FTC/TAF taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: Placebo tablet matched to BIC/FTC/TAF taken by mouth.
Study: NCT06121232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott® DRG / Abbott®/Medtronic® SCS
Description: Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants will not receive any intervention
Study: NCT05746559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single weight-based dose of placebo via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants will receive a single weight-based dose of ravulizumab via intravenous infusion.
Study: NCT05525936

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography and central venous pressure
Description: To perform an echocardiography, transthoracic or transesophageal and to measure central venous pressure through a central venous line.
Study: NCT06397027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by PO
Study: NCT06007274

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05279235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT001
Description: Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JT001 placebo
Description: Day 1: 600mg, Q12H X 1 day; Day 2\~5: 300mg, Q12H X 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Favipiravir
Description: Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
Study: NCT06114745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707 injection
Description: Drug: SHR-1707 SHR-1707 will be administered through IV infusion. Drug: Placebo Placebo will be administered through IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered through IV infusion
Study: NCT06505499

Intervention type: OTHER
Intervention: Gait Profile Score
Description: Gait Profile Score in degrees, calculated from kinematic raw data with the Gdi_GPS_calculator spreadsheet developed by Baker (2009).

Intervention type: OTHER
Intervention: Gait Visual Score
Description: Gait Visual Score in degrees, calculated from kinematic raw data with the Gdi_GPS_calculator spreadsheet developed by Baker (2009)
Study: NCT05378100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Infusion of ketamine 0.5 mg/kg over 40 minutes
Study: NCT05279235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir placebo
Description: Day 1: 1600mg, Q12H X 1 day; Day 2\~5: 600mg, Q12H X 4 days
Study: NCT05378100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Infusion of ketamine 0.5 mg/kg over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Infusion of ketamine 0.5 mg/kg over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Infusion of midazolam 0.05 mg/kg over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Infusion of midazolam 0.05 mg/kg over 40 minutes
Study: NCT05204797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted UKA
Description: Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and robotic assistance. Tourniquet will be used in all patients.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique UKA
Description: Cemented unicompartmental knee arthroplasty via mini-invasive medial approach and standard technique. Tourniquet will be used in all patients.
Study: NCT04518917

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mentally Singing
Description: Participants sing their song in their head and match their footfalls to the beat.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Listening to music
Description: Participants listen to their song and match their footfalls to the beat.
Study: NCT04266418

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: consume 1 sachet per day for 2 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Banana flower stamens extract
Description: consume 1 sachet per day for 2 months
Study: NCT06218602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Given by PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given by Infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given by Infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAR-T Therapy
Description: Given by Infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAR-T Therapy
Description: Given by Infusion
Study: NCT05099302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: divert attention
Description: In order to reduce the fears of the children who came to the waiting room before the operation, they watched cartoons and their attention was diverted to another point.
Study: NCT04983043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose QiShen YiQi Dripping Pills 3 bags
Description: Low dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 2 bags(0.52g dripping pills per bag) and QiShen YiQi Dripping Pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose QiShen YiQi Dripping Pills 3 bags
Description: High dose QiShen YiQi Dripping Pills contain QiShen YiQi Dripping Pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QiShen YiQi Dripping Pills placebo 3 bags
Description: QiShen YiQi Dripping Pills placebo contain QiShen YiQi Dripping Pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks
Study: NCT06356220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-Free Diet Education
Description: The two groups will receive different gluten free diet education interventions. Currently, virtual GFD education classes are the standard of care for educating children with CeD and their families about GFD at Boston Children's Hospital. Thus, all diet education (including GFFG intervention) will be provided virtually by Registered Dietitians with expertise in GFDs. .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet Education
Description: The two groups will receive different gluten free diet education interventions. Currently, virtual GFD education classes are the standard of care for educating children with CeD and their families about GFD at Boston Children's Hospital. Thus, all diet education (including GFFG intervention) will be provided virtually by Registered Dietitians with expertise in GFDs. .
Study: NCT05144698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-201 Rapamycin Resistant T Cells
Description: Autologous Rapamycin-Resistant Th1/Tc1 Cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Prior to RAPA-201 Therapy
Description: Carboplatin + Paclitaxel Regimen (CP Regimen)
Study: NCT06359951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project YES
Description: Digital SSI
Study: NCT05160272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-325
Description: Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching AP-325
Description: Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.